Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Endocrinol ; 141(2): 335-41, 1994 May.
Artículo en Inglés | MEDLINE | ID: mdl-8046304

RESUMEN

ZM 189,154 ([1RS,2RS]-2-(4-hydroxyphenyl)-2-methyl- 1-[9-(4,4,5,5,5-penta-fluoropentyl)sulphinylnonyl]-1,2,3,4- tetrahydronaphth-6-ol) is a non-steroidal pure antioestrogen. It has a high relative affinity for the oestrogen receptor, completely blocks the trophic action of oestradiol (OE2) on the uterus in immature and ovariectomized (OVX) adult rats and, in the latter, also completely blocks the trophic action of OE2 on vagina, bone and growth rate. ZM 189,154 displays no intrinsic oestrogen-agonist activity on uterus, vagina, bone, LH secretion or growth rate in OVX rats. Differential sensitivity of OE2-regulated processes was more apparent in intact rats. Daily doses of 0.6 mg/kg per day of ZM 189,154 blocked ovulation; 2 mg/kg per day achieved maximal uterine atrophy but did not affect bone density or growth rate; 10 mg/kg per day produced a broader spectrum of effects (reduced bone density, increased basal LH, slightly increased growth rate), but the magnitude of these was smaller than after ovariectomy; the 10 mg/kg dose also produced multiple ovarian follicular cysts. The failure of ZM 189,154 to achieve complete ovariectomy-like effects in intact rats may be due to the action of ovarian factors other than OE2, or to the circulating OE2 levels resulting from the disturbance to ovarian function posing too strong a challenge to the antagonist.


Asunto(s)
Huesos/efectos de los fármacos , Antagonistas de Estrógenos/farmacología , Ovulación/efectos de los fármacos , Tetrahidronaftalenos/farmacología , Útero/efectos de los fármacos , Animales , Unión Competitiva , Peso Corporal/efectos de los fármacos , Densidad Ósea/efectos de los fármacos , Femenino , Hormona Luteinizante/sangre , Tamaño de los Órganos/efectos de los fármacos , Folículo Ovárico/efectos de los fármacos , Ovariectomía , Ovario/efectos de los fármacos , Ratas , Receptores de Estrógenos/metabolismo , Tamoxifeno/química , Tamoxifeno/farmacología , Tetrahidronaftalenos/química , Tetrahidronaftalenos/metabolismo , Útero/anatomía & histología
2.
Immunology ; 70(2): 230-4, 1990 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-2142674

RESUMEN

The immunomodulatory properties of platelet factor 4 (PF4) have been examined in vitro and in vivo. This agent prevented the induction of concanavalin A (Con A)-induced suppressor cells in vitro in a dose-dependent manner but it did not affect the function of established Con A suppressor cells. This effect was not due to an enhanced production of interleukin-2 (IL-2) by lymphocytes exposed to PF4. The delayed-type hypersensitivity (DTH) reaction to sheep erythrocytes (SRBC) was used as a model for the generation of antigen-specific suppression in vivo. PF4 enhanced the magnitude of the swelling following SRBC challenge 10 days after sensitization by the i.p. route or following sensitization by both the s.c. and i.p. routes. These studies show that PF4 has immunomodulatory activities in well-defined models of cell-mediated immunity and suggest that this agent has a potential use in the dissection of events in antigen-specific suppression.


Asunto(s)
Concanavalina A/antagonistas & inhibidores , Hipersensibilidad Tardía/inmunología , Factor Plaquetario 4/farmacología , Linfocitos T Reguladores/efectos de los fármacos , Animales , División Celular/efectos de los fármacos , Células Cultivadas , Humanos , Activación de Linfocitos/efectos de los fármacos , Ratones , Ratones Endogámicos BALB C , Linfocitos T Reguladores/citología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA